Show simple item record

dc.contributor.authorEmmanouilidi, Aikaterini
dc.contributor.authorCasari, Ilaria
dc.contributor.authorAkkaya, B.G.
dc.contributor.authorMaffucci, T.
dc.contributor.authorFuric, L.
dc.contributor.authorGuffanti, F.
dc.contributor.authorBroggini, M.
dc.contributor.authorChen, X.
dc.contributor.authorMaxuitenko, Y.Y.
dc.contributor.authorKeeton, A.B.
dc.contributor.authorPiazza, G.A.
dc.contributor.authorLinton, K.J.
dc.contributor.authorFalasca, Marco
dc.date.accessioned2020-08-20T04:38:43Z
dc.date.available2020-08-20T04:38:43Z
dc.date.issued2020
dc.identifier.citationEmmanouilidi, A. and Casari, I. and Akkaya, B.G. and Maffucci, T. and Furic, L. and Guffanti, F. and Broggini, M. et al. 2020. Inhibition of the lysophosphatidylinositol transporter ABCC1 reduces prostate cancer cell growth and sensitizes to chemotherapy. Cancers. 12: Article No. 2022.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/80686
dc.identifier.doi10.3390/cancers12082022
dc.description.abstract

Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, recently, we have demonstrated that they can also have a more direct role in cancer progression. The pharmacological potential of targeting ABCC1, however, remained to be assessed. In this study, we investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models. Our data demonstrate that pharmacological inhibition of ABCC1 reduced prostate cancer cell growth in vitro and potentiated the effects of Docetaxel in vitro and in mouse models of prostate cancer in vivo. Collectively, these data identify ABCC1 as a novel and promising target in prostate cancer therapy.

dc.languageeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectABC transporter
dc.subjectABCC1/MRP1
dc.subjectDocetaxel
dc.subjectlysophosphatidylinositol
dc.subjectprostate cancer
dc.titleInhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy
dc.typeJournal Article
dcterms.source.volume12
dcterms.source.number8
dcterms.source.startPage1
dcterms.source.endPage19
dcterms.source.issn2072-6694
dcterms.source.titleCancers
dc.date.updated2020-08-20T04:38:42Z
curtin.note

© 2020 by the authors. Published by MDPI Publishing.

curtin.departmentSchool of Pharmacy and Biomedical Sciences
curtin.accessStatusOpen access
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidFalasca, Marco [0000-0002-9801-7235]
dcterms.source.eissn2072-6694
curtin.contributor.scopusauthoridFalasca, Marco [7004363047]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/